

PDL BioPharma

[View the current PDL BioPharma Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/27960-PDL+BioPharma.html)

(<http://www.bioportfolio.com/biocorporate/27960-PDL+BioPharma.html>)

Contact Details:

34801 Campus Drive

Fremont

California

94555

United States of America

Tel: 510-574-1400

Fax: 510-574-1500

Email: tpearce@pdl.com

PDL BioPharma is a leader in the discovery, development and marketing of innovative therapies for serious or life-threatening illnesses, commercially focused on the acute care, hospital setting. Our therapeutic emphasis is on the areas of hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer . Developing and commercializing innovative therapies for serious or life-threatening illnesses — this is what PDL BioPharma is all about. With a unique focus on the acute care, hospital-based setting, our research, development and commercial teams are working to bring new therapies to physicians and patients that we hope will improve and save lives. Today, our commercial products — Cardene I.V., Retavase and IV Busulfex — are helping patients with serious medical illnesses, while our research and development teams strive to bring important innovative new therapies to the forefront of tomorrow's patient care.

Recent Publications by PDL BioPharma:



- [Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.](#)
Humanization and modification of the Fc region of anti-human CD3 mAbs have... 1st August, 2009
PDL BioPharma 1400 Seaport Blvd Redwood City, CA 94063, USA.- J Neuroimmunol. 2009 Jul 25;212(1-2):65-73. Epub 2009 May 23. ([DOI Direct Link](#))
- [Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.](#)
Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have... 26th February, 2009
Research Department, PDL BioPharma, Redwood City, California 94063, USA.- Immunol Invest. 2009;38(1):76-92. ([DOI Direct Link](#))
- [NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures.](#)

Recent developments in high cell density and high productivity fed-batch... 19th November, 2008
Process Sciences and Engineering, PDL BioPharma, Inc., 1400 Seaport Blvd,- Biotechnol Bioeng.
2008 Nov 1;101(4):751-60. ([DOI Direct Link](#))

- [Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.](#)
Angiogenesis, the process by which new blood vessels form from existing... 10th June, 2008
PDL Biopharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.- Invest New Drugs. 2008
Feb;26(1):7-12. Epub 2007 Sep 1. ([DOI Direct Link](#))
- [A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.](#)
BACKGROUND: Integrins are important adhesion molecules that regulate tumor... 29th March, 2008
Department of Research, PDL Biopharma, Inc., Fremont, CA 94555, USA.- J Transl Med. 2007 Nov
27;5:61. ([DOI Direct Link](#))
- [Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies.](#)
We have developed a mammalian cell surface display vector, suitable for... 8th December, 2007
PDL BioPharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.- J Immunol Methods. 2007 Oct
31;327(1-2):40-52. Epub 2007 Aug 2. ([DOI Direct Link](#))
- [Validated alternatives: is immediate implementation required? Baluride: don't get taken for a ride.](#)
We have developed a mammalian cell surface display vector, suitable for... 25th July, 2007
PDL BioPharma, Fremont, CA, USA.- Lab Anim (NY). 2007 May;36(5):13. ([DOI Direct Link](#))
- [Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies.](#)
Presented is a novel antibody production platform based on the fed-batch... 30th June, 2007
Process Sciences and Engineering, PDL BioPharma, Inc., 34700 Campus Drive,- Biotechnol Bioeng.
2007 Feb 1;96(2):281-93. ([DOI Direct Link](#))
- [Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies.](#)
Presented is an antibody production platform based on the fed-batch... 30th June, 2007
Process Sciences and Engineering, PDL BioPharma, Inc., 34801 Campus Drive,- Biotechnol Bioeng.
2007 Feb 1;96(2):294-306. ([DOI Direct Link](#))
- [Cell based assays in drug development for biopharmaceuticals--IIR's Second Annual Conference.](#)
We have developed a mammalian cell surface display vector, suitable for... 9th February, 2007
PDL Biopharma Inc, 34801 Campus Drive, Fremont, CA 94555, USA.- IDrugs. 2006 Dec;9(12):841-5.
- [Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.](#)
Integrin alpha5beta1, the principal fibronectin receptor, is an important... 3rd February, 2007
PDL Biopharma- J Exp Ther Oncol. 2006;5(4):273-86.
- [Confirming human antibody responses to a therapeutic monoclonal antibody using a statistical approach.](#)
Confirmatory assays for immunogenicity testing typically involve testing a... 9th December, 2006
Preclinical and Clinical Development Sciences, PDL BioPharma, Inc.,- J Immunol Methods. 2006 Aug
31;315(1-2):80-7. Epub 2006 Aug 7. ([DOI Direct Link](#))

Press Releases on PDL BioPharma:

[Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th](#)

6th November, 2009 Helix BioPharma Corp.

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will

[Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts](#)

5th November, 2009 Helix BioPharma Corp.

AURORA, Ontario, Nov. 5 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the

[Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight](#)

5th November, 2009 Reportlinker

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline

[Cornerstone Therapeutics Reports Third Quarter 2009 Financial Results](#)

4th November, 2009 Cornerstone Therapeutics Inc.

-- Third quarter net revenues increased \$2.5 million to \$23.1 million, or 12%, compared to the third quarter of 2008 -- Non-GAAP income from operations(1) for the third quarter

[PDL BioPharma Announces Closing of \\$300,000,000 Securitization Transaction](#)

2nd November, 2009 PDL BioPharma, Inc.

INCLINE VILLAGE, Nev., Nov. 2 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it closed on its previously disclosed \$300 million securitization transaction

BioNews Results for PDL BioPharma



- [PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009](#)
Pharma Live: Oct 30 2009 5:26AM Matching: pdl biopharma
- [PDL BioPharma Announces Pricing of \\$300,000,000 Securitization Transaction](#)
Entrepreneur.com: Oct 30 2009 3:33PM Matching: pdl biopharma
- [PDL BioPharma Up 9.2% Since SmarTrend's Buy Recommendation](#)
TMC Net: Oct 30 2009 3:57AM Matching: pdl biopharma
- [PDL BioPharma Up 9.2% Since SmarTrend's Buy Recommendation](#)
Individual.com: Oct 30 2009 3:51AM Matching: pdl biopharma
- [PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009](#)
PR Newswire: Oct 29 2009 4:35AM Matching: pdl biopharma
- [PDL BioPharma Announces Pricing of \\$300,000,000 Securitization Transaction](#)
PR Newswire: Oct 29 2009 4:37AM Matching: pdl biopharma
- [Is PDL's Model Paying Off? Cash Payments to Shareholders Soon](#)

- BioWorld: Oct 29 2009 3:18AM Matching: pdl biopharma*
- [PDL BioPharma Announces Pricing of \\$300,000,000 Securitization Transaction](#)
SmartBrief: Oct 29 2009 12:47AM Matching: pdl biopharma
 - [PDL BioPharma Announces Pricing of \\$300,000,000 Securitization Transaction](#)
Genetic Engineering News: Oct 29 2009 12:08AM Matching: pdl biopharma
 - [PDL BioPharma Reschedules Third Quarter 2009 Financial Results Conference Call for 8:30 a.m. ET on October 28.](#)
PR Newswire: Oct 29 2009 4:35AM Matching: pdl biopharma
 - [PDL BioPharma Q3 2009 Earnings Call Transcript](#)
Seeking Alpha: Oct 29 2009 12:44AM Matching: pdl biopharma
 - [PDL BioPharma Narrows Guidance Lower](#)
Individual.com: Oct 29 2009 5:18AM Matching: pdl biopharma
 - [PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009](#)
Interest!ALERT: Oct 28 2009 1:48AM Matching: pdl biopharma
 - [PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009](#)
PDL BioPharma: Oct 28 2009 6:45AM Matching: pdl biopharma
 - [PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009](#)
Montana's News Station: Oct 27 2009 11:40PM Matching: pdl biopharma

PDL BioPharma Patents:



- 7435589- [Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer](#)
- 7183390- [Humanized antibodies to gamma-interferon](#)
- 7189507- [Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer](#)
- 7217797- [Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis](#)
- 7217798- [Alteration of Fc-fusion protein serum half-lives by mutagenesis](#)
- 7223393- [Amphiregulin antibodies and their use to treat cancer and psoriasis](#)
- 7276372- [Antibodies against GPR64 and uses thereof](#)
- 7276589- [Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis](#)
- 7285268- [Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis](#)
- 7288248- [Antibodies against cancer antigen TMEFF2 and uses thereof](#)
- 7361740- [Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis](#)
- 7365168- [Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis](#)
- 7381803- [Humanized antibodies against CD3](#)
- 7399469- [Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer](#)
- 7122185- [Anti-CCR5 antibody](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

